SMMT and AZN Related Headlines
Go Back- AstraZeneca closes $2 billion equity stake in Summit Therapeutics
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC
- AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- High-Stakes October has these Biotechs Entering Crucial Stretch
- Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target
- AstraZeneca invests $2B in Summit Therapeutics preferred shares
- AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
SMMT and AZN Related Press Releases
Go Back- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- High-Stakes October has these Biotechs Entering Crucial Stretch
- AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
